Indian russian pharma challenges
This presentation is the property of its rightful owner.
Sponsored Links
1 / 24

Indian & Russian Pharma Challenges PowerPoint PPT Presentation


  • 187 Views
  • Uploaded on
  • Presentation posted in: General

Indian & Russian Pharma Challenges. C.K.Kamalakkannan Country Head – Russia Sun Pharmaceutical Industries Ltd. Global Pharma Market Highlights 2010. Pharma Market Value US$ 856 billion with Growth 4.1% Generic Drug Market – US$ 234 billion US Pharma Market – US$ 310.6 billion

Download Presentation

Indian & Russian Pharma Challenges

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Indian russian pharma challenges

Indian & Russian Pharma Challenges

C.K.Kamalakkannan

Country Head – Russia

Sun Pharmaceutical Industries Ltd.


Global pharma market highlights 2010

Global Pharma Market Highlights 2010

Pharma Market Value US$ 856 billion with Growth 4.1%

Generic Drug Market – US$ 234 billion

US Pharma Market – US$ 310.6 billion

European Markets – US$ 147.4 billion

(Germany, France, Italy, Spain and UK )

17 Pharmerging Countries US$ 150.5 billion

( China, India, Russia, Poland, Argentina, Mexico, Vietnam, South Africa, Thailand, Indonesia, Romania, Egypt, Pakistan & Ukraine )


Global pharma market outlook

Global Pharma Market Outlook

2011 – expected to grow by 5 – 7 % ; reach US$ 880 billion

2015 -- expected to reach – US$ 1,1 trillion

2015 -- US pharma market will reach between – US$ 320 to 350 billion

2015 -- Pharmering Markets – Expected between US$ 285 to 315 Billion.

2015 -- European Market will reach – US$ 160 billion


Summary global pharma in 2015

SUMMARY – GLOBAL PHARMA in 2015

Pharmerging Markets & Generics are the key drivers for Growth

17 Pharmerging countries expected to contribute 28% of Global market and expected to double their spending on Medicines $ 285 - $ 315 by 2015 ( $ 151 billion in 2010 )

Global Pharma market share for Generics expected to grow from 27% to 39%

Global Pharma market share for Patented medicines is expected to decline from 64% in 2010 to 53% in 2015


India pharma market highlights 2010

INDIA PHARMA MARKET HIGHLIGHTS 2010

  • Indian Pharma market ranks 10th in terms of Value and 3rd in terms of Volume

  • Indian Pharma market – US$ 12.3 billion in 2010

  • Branded Generics 70-80% & a small % of unbranded generics

  • Indian Pharma to grow at a CAGR of 12-14% between 2009 – 2015 to Reach US$ 20-24 billion by 2015

  • Indian Pharma market to Reach US$ 55 billion by 2020


India pharma market highlights

INDIA PHARMA MARKET HIGHLIGHTS

  • Exports : US$ 13.9 Bn Formulation export : US$ 5.8 Bn & API export : US$ 8.1 Bn

  • Exports branded generics CAGR 21- 23% during 2009 – 2014

  • India contributes around 10% of world’s production by volume and 1.5% by value

  • Over 10,500 manufacturing units in India

  • 3000+ pharma companies

  • Over 60,000 formulations, covering almost every therapeutic segment


India pharma market highlights1

INDIA PHARMA MARKET HIGHLIGHTS

  • R&D investment by the Global Pharma industry, estimated at US$ 40-50 billion in India over the next 10 years

    Clinical trials : 65% & New drug discovery : 35%

  • Innovative drug discovery with about 235 Clinical Trials is underway on about 13,000 patients in the areas of CVD, Cancer, Diabetes, Psychiatry, Infections

  • Number of Clinical trials is anticipated to cross 2000 by 2013

  • Skilled Labour costs are 50 to 55% more economical than in the West


India pharma market highlights2

INDIA PHARMA MARKET HIGHLIGHTS

Approved Manufacturing Facilities

  • The largest number of US FDA approved facilities outside US are in India

  • 153 EDQM (European Directorate of Quality Medicine) bulk drug facilities have been approved

  • The country has 153 EDQM approved facilities for 195 molecules out of the total 693 molecules approved by EDQM

  • India also has over 1,200 WHO GMP Certified Plants

    Formulations

  • Manufactured for therapeutics – Largest share from Anti-diabetics, Neuro/CNS , Cardiovascular, Respiratory, Anti-infective & Pain killers

  • India exports formulations in large volumes to Semi Regulated Markets – Africa, Asia, CIS & Latin America


Opportunities indian pharma for collaboration

Opportunities – Indian Pharma for Collaboration


Opportunities indian pharma summary

Opportunities – Indian Pharma Summary

  • Wide range to offer APIs, Branded Generics and Generics in Top segments which, as per Global pharma market is expected to generate huge volumes in 2015

  • Offers contract Mfg. facilities & Supplies of semi finished formulations

  • Offers R & D – Drug discoveries and Development – Clinical trials organizations

  • Contract & Co-marketing alliances

  • Offers cost effectiveness in most of the pharma industries activities than West


Sun pharma highlights 2010 11

Sun Pharma – Highlights 2010 - 11

  • Annual sales grew 50%

  • Indian branded generics grew 37%

    Product basket includes 537 formulations

    Market leader in chronic segments

    Specialize in technically complex products & complete therapy basket – Remain competitive in the market

    Launched 38 new products in 2010 -11

  • Emerging Market - branded generic business grew 32%

  • International operations grew across 41 markets


Sun pharma highlights 2010 111

Sun Pharma – Highlights 2010 - 11

  • Presence in International Branded Generics in 41 countries

  • 14 key Deals & acquisitions – From 1996 to 2011

  • Successful acquisition of Taro pharma – Sun Pharma holds an economic stake of 66% and enjoys voting rights of 77% in Taro

  • Sun Pharma and MSD (India) entered a Strategic Partnership to co-market MSD's diabetes drugs, sitagliptin and sitagliptin plus metformin

    • Sun Pharma and Merck establish a Joint Venture for Emerging Markets excluding India

    • Opportunity to use SPARC Proprietary Delivery Technologies

    • Equal representation in JV for Sun Pharma & Merck

    • JV to use partners infrastructure for development, manufacturing, regulatory and commercialization


Finished dosage manufacturing

Finished Dosage Manufacturing

15 Manufacturing sites worldwide

  • India : 6, US : 3, Canada : 1

  • Capacities available for a variety of finished dosage

Creating Lasting Value - Investor Presentation


Api manufacturing

API Manufacturing

APIKey Plants

8 World class locations with all sites ISO 14001, ISO 9002 approved

  • India : 5, Israel : 1, US : 1, Hungary : 1

Over 25 API processes scaled up annually

Hungary & Tennessee (US)

Panoli & Ahmednagar (both India)‏

  • International regulatory approvals: USFDA, European

  • Stand alone units for peptides, anti-cancer, steroids, sex hormones

  • Controlled substances manufacture

Creating Lasting Value - Investor Presentation


Research and development

Research and Development

Immediate termANDA, DMF, Products for India

Medium termDrug delivery systems

Balancing the risk

  • Generic R&D spend around 6% of net sales

  • Strong research teams in generics, finished dosage development, biological support, chemistry

  • 4 R&D centers with about 800 scientists

Mumbai

Baroda

Creating Lasting Value - Investor Presentation


Sun pharma opportunities

Sun Pharma – Opportunities

  • To offer Branded Generics and Generics in Top segments in which Global pharma market is expected to grow faster

  • Offer APIs in Globally growing top segments

  • Ability to bring new combinations and formulations of incrementally innovative, branded generics to market

  • Opportunity to use SPARC Proprietary Delivery Technologies

  • JV to use partners infrastructure for development, manufacturing, regulatory and commercialization

  • Open for the Opportunity to Co-marketing alliances


Russia pharma market

Russia Pharma Market

  • 2010 - Russia-10th Largest Pharma Mkt. $ 14 bn., Gr. 11%

    • 80% import & 20% local

  • In Pharma business - Brand loyalty is high

  • Govt. plan investment on healthcare - $ 6 bln. By 2015 to develop healthcare facilities & local capabilities

  • Reduce Import from 80% to 50% by 2020


Russia pharma opportunities

Russia Pharma - Opportunities

  • Russian Pharma Market – forecasted over all growth 12% to 15% per annum for the next few years

  • Requirement of Branded Generic & Generic – to support Govt. programs

  • OTC & Rxtion segment is growing faster

  • Govt. 2020 programs provides opportunity for Investment in Russian Pharma sector


Challenges russian pharma market

Challenges - Russian Pharma Market

Product Registrations

  • Product under registration & New registration – BE /CT to be submitted along with the documents as per recent information – demand of Local BE further delays the process of registration

    Suggestion for BE :

    1. Accepting the BE from Russian govt. approved centers in India

    2. MOH delegation to visit companies’ in-house BE center for approval

    Suggestion for Clinical Trial :

    1. Accepting CT conducted in other countries and accept other countries’ registration

    2. Post-registration clinical trial


Challenges russian pharma market1

Challenges Russian Pharma Market

Product Registration

Impurity Limits – Compared with analogue products NDs registered in Russia

Suggestion

Possibility of  consideration and accepting  of Normative documentation data according to  USP or BP pharmacopeias and Limits approved in Europe instead of   comparing   with  analogical  products  NDs registered  in Russia

First Generic product Registration

In the absence of innovator difficult to register Generic product in Russia - it is required to submit all the documents like for Original product

Suggestion

Consideration given to generic products on submission of documents like BE from approved centers or BE from EU…Post registration clinical trial.. etc.


Challenges russian pharma market2

Challenges Russian Pharma Market

Operational

1. Registration of prices for life-saving products considers only customs charges to be included in the cost of the product. Other incidental expenses like transport, certification charges, demurrage and storage charges not considering as a factual expense to be included in the cost of the product. Since, in the local margin there is a cap (limited margin).. and these expenses not considered to include in the cost of the product.. Overall companies incurring loss.

Suggestion :

All actual cost spent officially to clear the product to be considered ( with documents ) to include in the cost of the product.

2. For Life-saving drugs Cap on Local margin: Companies get less than 5 % which is very low to meet the overall cost of operation.

There are issues with Tax Dept. to justify the low margin and high cost operation (Over all profitability)

Suggestion :

1. Fixing margins at each level / re-consider the margin %

2. For Life-saving drugs, supply with low margin. Tax. Dept. to give consideration on the justification provided by the company with documents.


Support from russian govt moh

Support – From Russian Govt. MOH

  • Price Registration or Price caping – Consideration given on Molecule not on Company or Country Specific

  • Fast Track Registration on Green Field Projects

  • Clarity on policies, Benefits & Tax holidays for 5 years – FDI on Mfg. facility projects

  • In Regulatory : Training, Cooperation & Dialogue between both countries’ regulatory bodies – for better understanding to use both countries’ strength to overcome Regulatory challenges


  • Login